43 results on '"Bolanos, Lyndsey"'
Search Results
2. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
3. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia
4. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
5. Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network
6. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies
7. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
8. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
9. Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
10. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
11. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia
12. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity
13. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia
14. UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies
15. The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia
16. Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies
17. Regulation of Metabolic Homeostasis By TRAF6 Contributes to the Leukemia Progression
18. UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies
19. Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity
20. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways
21. Overcoming adaptive therapy resistance in AML by targeting immune response pathways
22. Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies
23. TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis
24. Erratum: Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
25. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
26. Inhibition of UBE2N As a Therapeutic Approach in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
27. TRAF6 Is Essential for Maintaining Hematopoietic Stem Cell Homeostasis
28. Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia
29. TRAF6 Mediates Basal Activation of NF-kB Necessary for Hematopoietic Stem Cell Homeostasis.
30. Innate Immune Signal Pathway Activation Induced By Combined Loss of Del(5q) MDS Genes, Tifab and Mir-146a, Accelerates Hematopoietic Stem Cell Exhaustion Driven By Chronic Exposure to a TLR Ligands
31. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival
32. A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
33. Differential IRAK signaling in hematologic malignancies
34. Disease-Relevant Expression Of TRAF6 In Mouse HSC Results In An MDS-Like Disease
35. SQSTM1/p62 Is a Necessary Cofactor In MDS/AML With Deletion Of Mir-146a
36. Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-κB
37. Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-κB Signaling in MDS/AML.
38. Degradation of TRAF6 by Bortezomib-Induced Autophagy Contributes to Cell Death in Acute Myeloid Leukemia and Myelodysplastic Syndrome
39. Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
40. Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
41. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
42. ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.
43. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.